Brain
Alzheimer disease
The commonest dementia of old age: amyloid plaques and tau tangles accompany loss of cortical neurons and acetylcholine, with atrophy of the frontal, parietal and temporal lobes.
Causes et facteurs de risque
- Age: over 40% of people older than 85 are affected
- Familial in 5–10%: APP (chromosome 21), presenilin 1 and 2
- The ε4 allele of apolipoprotein E
- Down syndrome (symptoms before 50)
Aspect macroscopique
- Cerebral atrophy with narrowed gyri and widened sulci, mainly frontal and parietal, also temporal, sparing the occipital lobes.
Au microscope
- Neuritic plaques: extracellular amyloid β (from amyloid precursor protein) with dystrophic neurites, in the neocortex and hippocampus.
- Neurofibrillary tangles: hyperphosphorylated tau within neurons.
Évolution
- Amyloid β accumulates in plaques; tau forms tangles in neurons.
- Cortical neurons and their acetylcholine are lost.
- The cortex atrophies, worst in the frontal, parietal and temporal lobes and the hippocampus.
- 5 to 10 years from onset: Progressive memory loss, then aphasia and immobility, until death.
Complications
- Progressive loss of memory and of the ability to carry out daily activities
- Death typically 5 to 10 years after onset
Examens complémentaires
- Cognitive testing
- Impaired memory first, then other cognitive domains.
- Blood tests
- Exclude treatable causes of cognitive decline, such as low vitamin B12 or hypothyroidism.
- MRI
- Atrophy of the hippocampus and cortex; excludes other causes.
- CSF biomarkers or amyloid PET
- Low amyloid-β42 and raised tau in the CSF, or amyloid deposition on PET.
- Neuropathology
- Definite diagnosis: amyloid plaques and neurofibrillary tangles at autopsy.
Traitement médicamenteux
- Cholinesterase inhibitors (for dementia): Drugs that slow the breakdown of acetylcholine in the brain, partly compensating for the loss of cholinergic neurons in Alzheimer disease; they modestly improve symptoms but do not stop the disease.
- Memantine (NMDA receptor antagonist): An NMDA receptor antagonist that damps excessive glutamate stimulation, which may contribute to neuronal injury; used in moderate to severe Alzheimer disease, alone or with a cholinesterase inhibitor.
Anatomie concernée
Rédigé d’après
- Robbins and Cotran Atlas of Pathology, 3rd ed., Ch. 19, The Central Nervous System, pp. 532–533, figs 19-112 to 19-114
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.